Facebook Twitter Instagram
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Facebook Twitter Instagram
    Pharmacognosy Communications
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Pharmacognosy Communications
    retyeyutreu
    Original Article

    Antibacterial Activity and Toxicity Profiles of Selected Medicinal Plant Extracts and Conventional Antibiotics against Bacterial Triggers of Some Autoimmune Diseases

    Web AdminBy Web AdminJuly 5, 2024Updated:July 6, 2024No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn WhatsApp Pinterest Email

    Amadeus Cocis1, Ian Edwin Cock1,2,*
    1School of Environment and Science, Griffith University, Nathan, Queensland, AUSTRALIA.
    2Centre for Planetary Health and Food Security, Nathan Campus, Griffith University, Nathan, Queensland, AUSTRALIA.
    DOI: 10.5530/pc.2024.3.16

    ABSTRACT 

    Background: Nigella sativa L., Anongessius latifolia (Roxb. ex DC.) Wall. ex Euill. and Perr. and shilajit have been used traditionally to treat numerous infectious diseases, including many caused by bacterial pathogens. However, extracts of these traditionally medicines have been poorly studied and are yet to be tested for the ability to inhibit the growth of bacterial triggers of multiple sclerosis and rheumatic fever. Materials and Methods: Antimicrobial activity of selected plant extracts was assessed using disc diffusion and liquid dilution minimum inhibitory concentration (MIC) assays against some bacterial triggers of multiple sclerosis and rheumatic fever. Interactions between the extracts and conventional antibiotics were studied and classified using the sum of the fractional inhibitory concentration (ΣFIC). The toxicity of the individual samples and the combinations was assessed using the artemia lethality assay (ALA) assay. Results: The methanolic A. latifolia extract displayed notable antibacterial activity against the bacterial triggers of multiple sclerosis (A. baylyi and P. aeruginosa), and rheumatic fever (S. pyogenes). Furthermore, combining the methanolic A. latifolia extract with tetracycline and chloramphenicol resulted in potentiation of the inhibitory activity against P. aeruginosa and S. pyogenes. None of the individual components (nor the combinations) were toxic in the ALA assay. Conclusion: The A. latifolia methanolic displayed clinically relevant antibacterial activity against A. baylyi, P. aeruginosa and S. pyogenes when tested alone. Furthermore, that extract also potentiated the activity of tetracycline and chloramphenicol against some bacteria. The lack of toxicity of the extracts and combinations indicates that these combinations may provide leads in the development of new therapies to prevent and treat the autoimmune diseases multiple sclerosis and rheumatic fever.

    Keywords: Medicinal plants, Black caraway, Multiple sclerosis, Rheumatic fever, Conventional antimicrobials, Synergy, Drug interaction, Toxicity.

    DOWNLOAD PDF
    Original Article
    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    About Journal
    About Journal

    Pharmacognosy Communications [Phcog Commn.] is a quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.
    Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
    Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.
    Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.

    © 2025 Pharmacognosy Communications. Maintained by Manuscript TechnoMedia LLP.

    Type above and press Enter to search. Press Esc to cancel.

    Scroll Up